Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

MIBREAST Making in Immediate Breast REconstruction And the Measurement of the EffectS of RadioTherapy

Sponsor: Royal Marsden NHS Foundation Trust

NCT ID: NCT07136753

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 72 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor

In plain English

This study, run by the Royal Marsden NHS Foundation Trust, looks at breast reconstruction surgery given straight away after a mastectomy (removal of the breast) for breast cancer or to reduce risk, and how radiotherapy affects it. It uses 3D-SI, a type of imaging, to take measurements at set times. The exact aim of the measurements is not stated — ask the trial team.

Who can take part

  • Women aged over 18
  • Having breast reconstruction straight away after a mastectomy for breast cancer, or as a risk-reducing step
  • Able to attend 3D-SI imaging appointments at set times

Who may not be able to

  • Unable to give consent (lack of capacity)
  • A language barrier that makes the English questionnaires hard to understand
  • Visual impairment
  • Unable to complete the study questionnaires
  • A disability that may make positioning for imaging difficult
  • Unable to attend for photographs
  • Needing delayed reconstruction, or no longer considering reconstruction

What taking part involves

  • • Not stated — ask the trial team

Time commitment: Attending 3D-SI imaging appointments at specified intervals and completing study questionnaires; total duration not stated — ask the trial team.

Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.

Type of study
Observing health over time
Ages
18 Years and over
Who
Female
Number of participants
300
Started
2024-09-12
Last checked
2025-08

Plain English Summary

What is this study?

  • • Testing a new treatment for breast cancer
  • • Clinical study - 300 participants
  • • Patients who require a removal of a breast (mastectomy) for breast cancer or future risk reduction often have immediate breast reconstruction (IBR)

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with breast cancer
  • • Female only

Where?

  • • London - Royal Marsden NHS Foundation Trust

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Patients who require a removal of a breast (mastectomy) for breast cancer or future risk reduction often have immediate breast reconstruction (IBR). This can be performed using either an implant or the patient's own body fat to recreate the breast shape. Patients can find it difficult to imagine their own post-surgery appearance. Using 3D surface imaging (3D-SI) can change a patient's pictures to show them how they might look after surgery, known as a simulation. Some patients may find 3D-SI and simulation gives them confidence in their expectations and others may not feel it helps much. This study will investigate the following 3 questions: 1. Whether 3D-SI and simulation can improve patient confidence about their likely post-surgery appearance 2. Whether 3D-SI measurement of breast shape helps in surgical planning and reduces the need for later adjustment surgery to improve symmetry, especially in patients having a mastectomy on one side only 3. How much radiotherapy changes breast reconstructions over time using 3D- SI to objectively measure this. For this study the follow up for some women who do and some who do not have radiotherapy after breast reconstruction. 3D surface imaging may improve surgeon understanding of breast shape, prior to surgery. In cases where there is a high risk of breast cancer recurrence patients are offered radiotherapy to the breast, either before or after surgery. Radiotherapy has a negative impact on the reconstructed breast, and may cause it to shrink and change position but the effect of radiotherapy has never been accurately quantified. This study will be investigating the following: 1. Whether 3D-SI measurement of breast shape helps in surgical planning and reduces the need for later adjustment surgery to improve symmetry, especially in patients having a mastectomy on one side only 2. How much radiotherapy changes breast reconstructions over time using 3D- SI to objectively measure this. For this study the follow up some women who do and some who do not have radiotherapy after breast reconstruction.

More detail

Approximately 40% of all women diagnosed with breast cancer (BC) will require a mastectomy and a large proportion (60%) of these will choose to have an immediate breast reconstruction (IBR). Patient satisfaction with physical appearance after completion of their BC treatment has a well-documented association not only with their psychological wellbeing but also improved quality of life. Due to advances in oncological therapies, BC patients now have excellent survival rates of 85% at five years and 75% at ten years meaning that more women survive to experience the long-term impact of surgical and radiotherapy treatments and highlights the importance of improving aesthetic outcome as a survivorship focus. 3D-surface imaging (3D-SI) and simulation is frequently used to demonstrate cosmetic breast augmentation outcomes in the private sector and is increasingly being used in breast cancer surgery. Effective communication of the post-operative aesthetic outcome and the possible requirement of adjustment surgery to patients is a central part of the informed consent process. Women sometimes struggle to decide between breast-conserving treatment and mastectomy with or without reconstruction. Those that want reconstruction to have the option of using a silicone implant, or their own tissue, transplanted from the abdomen or inner thigh (an autologous flap). Consultations focus on the patient's desires and expectations, and the surgeon's explanation of what is technically possible, the benefits and compromises, until a mutual understanding is reached. This can however be challenging, particularly when attempting to predict the effects of adjuvant radiotherapy on the reconstructed breast. Traditionally, surgeons have used diagrams or 2D clinical photographs of other patients who have had surgery to demonstrate the predicted post-operative appearance. Many patients have reported that they find these methods unhelpful and confusing, as the wide variety of body habitus, breast shape, skin tone and surgical options mean that it is unlikely that a woman will see images adequately illustrating her own unique outcome. The hypothesise that viewing 3D simulations of their own likely appearance after mastectomy and breast reconstruction will give women more confidence and certainty as they approach surgery. There are not yet in a position to use 3D-SI as a decision-support tool. The overarching aim of this study is to evaluate the utility of 3D-SI in simulation and measurement of outcome of immediate breast reconstruction. Hypothesis 1 - Impact of 3D Simulation on Shared Decision Making Women who see a simulation of their IBR outcome will have more confidence in their decision-making about IBR options. Hypothesis 2 - Impact of 3D-SI on Elective Surgical Revision rate A better understanding of breast shape may reduce the need for elective surgical revisions such as volume-adjustment procedures (lipofilling or liposuction) in the reconstructed breast. Hypothesis 3 - Impact of Radiotherapy on IBR The hypothesise that immediate breast reconstructions that receive radiotherapy undergo greater change in shape and position over time.

Breast Cancer

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: Female only

What the study is looking for

  • ✓Female
  • ✓Aged \> 18
  • ✓Undergoing immediate breast reconstruction (autologous or implant based) follow mastectomy for breast cancer or as a...
  • ✓Available to attend 3D-SI appointments at specified intervals

Who cannot take part

  • ✗Lack of capacity
  • ✗Language barrier that prevents patients from understanding the English questionnaires
  • ✗Visual impairment
  • ✗Unable to answer study questionnaires
  • ✗Disability that may prevent appropriate positioning during the imaging process
See the full criteria
Inclusion Criteria: * Female * Aged \> 18 * Undergoing immediate breast reconstruction (autologous or implant based) follow mastectomy for breast cancer or as a risk-reducing strategy * Available to attend 3D-SI appointments at specified intervals Exclusion Criteria: * Lack of capacity * Language barrier that prevents patients from understanding the English questionnaires * Visual impairment * Unable to answer study questionnaires * Disability that may prevent appropriate positioning during the imaging process * Unable to attend for photography * Requiring delayed reconstruction or no longer considering a reconstruction

Where Is This Study? (1 UK site)

Royal Marsden NHS Foundation Trust

London, United Kingdom

Recruiting
Site contact (verified)
Jennifer RusbyPrincipal Investigator

How to Get in Touch

Jeane Guevara

Sponsor contact

CONTACT

+44 20 3186 5420 MIBREAST@rmh.nhs.uk
Data sourced from ClinicalTrials.gov · Last verified: 2025-08